SLC5A2 and chronic kidney disease: In all, given the life-saving and mortality-reducing benefit of SGLT2 inhibitors in patients with heart failure, chronic kidney disease, and CVD [56], which currently is unequivocally acknowledged in all international guidelines, watchful monitoring of the millions of patients on SGLT2 inhibitor therapy should be undertaken, keeping the common ground concept of the high-risk CRM–cancer cluster in mind.